VistaGen Therapeutics said it received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for a patent application related to methods of treating depression with AV-101, its oral new generation glutamatergic product candidate in Phase 2 development for treatment of Major Depressive Disorder (MDD).
VistaGen said that when issued, the patent will not expire until at least 2034.
“This Notice of Allowance from the USPTO is a major development, representing one of the most significant patent applications ever allowed to our company,” said VistaGen CEO Shawn Singh.
“This patent will be one of the core components of our commercial protection strategy for AV-101 in the U.S., the world’s largest pharmaceutical market.
“It will both enhance and expand substantially our U.S. market exclusivity for AV-101.
“We are continuing to pursue additional patents for AV-101, in the U.S. and other major pharmaceutical markets, to further fortify our global patent portfolio for this promising CNS drug candidate.”